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Purpose: High-Performance System (HPS) laser photo vaporization of the prostate (PVP) is a widely used procedure nowadays. The 
safety and efficacy of the procedure has been affirmed in general patients with benign prostatic hyperplasia (BPH), but data on the safety 
and efficacy in specific situations, such as in patients with a large prostate, patients taking anticoagulant or 5-alpha reductase inhibitor (5-
ARI) medication, and patients with a history of acute urinary retention (AUR) or previous transurethral resection of the prostate (TURP), is 
lacking. We investigated the safety and efficacy of HPS laser PVP in these unique patient groups.
Methods: The study was conducted from March 2009 to February 2012 among patients for lower urinary tract symptoms. Patients 
in whom BPH was diagnosed and who were treated with 120-W HPS GreenLight PVP were selected. Patients were divided into groups 
of prostate size above and below 80, anticoagulant medication, 5-ARI medication, AUR history, and TURP history on the basis of the 
preoperative history and physical examination.
Results: A total of 533 patients observable for a follow-up period of more than 6 months were enrolled as the study population. 
The patients’ mean preoperative prostate size was 51.0±32.7 mL and their mean prostate-specific antigen was 4.5±27.9 ng/mL. The 
average operating time was 24.5±12.2 minutes and the average applied energy during surgery was 152,184±89,495 J. Postoperative 
objective and subjective parameters in all groups were significantly improved compared with preoperative values.
Conclusions: Laser resection of the prostate is safe and effective. The results of HPS laser PVP were not influenced by prostate size, 
the use of anticoagulants, the intake of 5-ARI for BPH management, a history of AUR, a history of TURP, or other factors. Thus, this study 
was able to reconfirm the efficacy and safety of laser resection of the prostate.  
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a disease exhibiting one 
of the fastest surging incidences because the elderly population 
is rapidly growing [1]. The complications of BPH, including 
urinary retention, urinary infection, reduced renal function, 
and indwelling urinary catheter, eventually lead to reduced 
social activities in particular [2]. These problems brought a 
rapid increase in social expenses from 4 billion to 26 billion 
dollars annually, a trend that is continuously increasing at 
the moment [3]. This fact implies that medical costs could be 
saved to a great extent if BPH were properly managed in our 
society. 
 Various treatment methods have been introduced and 
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implemented from medications regulating BPH symptoms 
to medications reducing the size of the prostate to surgical 
methods of removing the enlarged part of the prostate. Trans-
urethral resection of the prostate (TURP) is the gold standard 
for surgically removing the enlarged part of the prostate. Now-
adays, however, laser surgical procedures are frequently used. 
 After the first laser resection of the prostate was implement-
ed, the efficacy and safety of the procedure were reported in 
numerous studies. Among the currently reported laser surgi-
cal methods, the efficacy and safety of High-Performance 
System (HPS) laser therapy, in particular, have been verified 
through many studies. However, most previous studies com-
prised ordinary BPH patients. Hence, studies on rare cases 
that could be encountered in the actual clinical field are still 
inadequate in number. The results of 120-W HPS laser photo 
vaporization of the prostate (PVP) are vague in cases with 
larger sized prostates, the use of anticoagulants, the intake of 
5-alpha reductase inhibitor (5-ARI) for prostate enlargement 
regulation, a history of acute urinary retention (AUR) owing 
to preoperative prostate enlargement, and a medical record 
of BPH-related surgery. The authors of this study intended to 
investigate the postoperative progress of patients who were 
observable for a follow-up period of more than 6 months and 
who fell under the above conditions owing to our performance 
of more than 500 HPS laser surgeries over the last 3 years. 
METHODS
1. Study population
The study was conducted from March 2009 to February 2012 
among patients who visited a Urology Clinic for lower urinary 
tract symptoms (LUTS). Patients in whom BPH was diag-
nosed and who were treated with 120-W HPS GreenLight PVP 
were selected. Operative indications were based the Ameri-
can Urological Association and European Urological Associa-
tion guidelines on BPH, maximum urinary flow (Qmax) < 15 
mL/sec, postvoiding residual volume (PVR) > 100 mL, and 
International Prostate Symptom Score (IPSS) > 7. Also, symp-
tom persistence despite proper management, avoidance of 
proper medication, severe bladder outlet obstruction (BOO) 
revealed by urodynamic study, bladder stones, recurrent 
urinary tract infections, and persistent hematuria from the 
prostate were added as operative indications.
 Patients were divided into groups of prostate size above 
and below 80, anticoagulant medication none/yes, 5-ARI 
medication none/yes, AUR history none/yes, and TURP his-
tory none/yes on the basis of the preoperative history and 
physical examination results. 
 This study was conducted under Seoul St. Mary’s Hospital 
Institutional Review Board (IRB) approval. The IRB approval 
number is KC12RISI0800.
2. Operative technique
After general or spinal anesthesia, the operation was done by a 
single surgeon. A continuous running irrigation system with a 
22-Fr resectoscope with a 30-degree lens and a 75-degree laser 
fiber was used. Normal saline (0.9%) was used for irrigation. 
The 120-W HPS GreenLight laser PVP was done at a 1-mm dis-
tance from the prostate tissue for optimal vaporization effect. 
Vaporization was initiated at the bladder neck in a clockwise 
direction, pulling the resectoscope out and rotating the laser 
fiber simultaneously. An 18-Fr urethral catheter was placed 
after the operation and removed the next day, taking into con-
sideration the degree of hematuria.
3. Follow-up
The patients visited the outpatient clinic 1, 3, 6, 9, and 12 months 
after the operation. At every visit, the patients completed IPSS 
questionnaires and Qmax and PVR were checked. In addition, 
the presence of postoperative complications was verified at 
every follow-up visit.
4. Statistical analysis
A Student t-test was used to compare the preoperative inter-
group differences and repeated-measures analysis of variance 
(ANOVA) was used to compare the preoperative and post-
operative values. P-values of less than 0.05 were defined as 
statistically significant.
RESULTS
A total of 533 patients observable for a follow-up period of 
more than 6 months were enrolled as the study population. 
The mean age of the subjects was 70.8 ± 8.1 years. Their mean 
preoperative prostate size was 51.0 ± 32.7 mL, and their mean 
prostate-specific antigen (PSA) concentration was 4.5 ± 27.9 
ng/mL. Concerning significant medical history, 5 cases of 
120-W HPS laser PVP were performed owing to severe dys-
uria after a patient was diagnosed with prostate cancer. 
 The average operating time was 24.5 ± 12.2 minutes and the 
average applied energy during surgery was 152,184 ± 89,495 J. 
The average catheterization time was 1.39 ± 3.48 days. 
 Significant differences were observed in prostate size, PSA, 
Qmax, and PVR in the groups formed according to preopera-
tive prostate size. However, no significant differences were 
found except for age in the comparison of the use of antico-
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agulant medication. A significant difference was shown for 
PSA only in the comparison of the use of 5-ARI medication. 
According to the comparison of AUR history, significant dif-
ferences were identified in age, transrectal ultrasound, PSA, 
and PVR. Moreover, significant differences were detected in 
age and PVR in the comparison of previous history of TURP 
(Table 1). 
 The results of the IPSS questionnaire completed by all pa-
tients at postoperative months 1, 3, 6, 9, and 12 are shown in 
Fig. 1. A significant difference from preoperative values was ob-
served in the IPSS questionnaire during the follow-up period 
(P < 0.05 compared with preoperative value). Moreover, the 
results of the IPSS questionnaire conducted on each group at 
postoperative months 1, 3, 6, 9, and 12 are shown in Fig. 2. 
 IPSSs decreased compared with preoperative values in 
all groups (P < 0.05). Moreover, an increase in postoperative 
Qmax and a decrease in postoperative PVR were observed. 
The results of the repeated-measures ANOVA are shown in 
Table 2. Most postoperative IPSS, Qmax, and PVR values were 
found to be changed. However, no significant change was 
observed in postoperative PVR scores in the group who had 
undergone TURP before. Discriminating variables were in-
significant in most cases in the subgroup analysis. However, 
a difference was identified in quality of life (QoL) in case of 
prostate volume above or below 80. A difference was found in 
the IPSS total score in the case of a presence of AUR history. 
Furthermore, a lack of significant difference was confirmed 
in the results verified by time-adjusted P-value. 
 Bleeding requiring transfusion or suspension of surgery 
did not happen during the operation. Although some patients 
reported dysuria after surgery, most subjects were able to 
regain regular urinary function from the second urination 
because preoperative transrectal biopsy was simultaneously 
performed in patients with high PSA. During the follow-up 
period, no cases required reoperation due to worsened symp-
toms or gross hematuria. Although dysuria was observed in 
Table 1. Preoperative demographic data of each group
Variable No.
Age  
(yr)
TRUS
PSA  
(ng/mL)
IPSS  
total
IPSS  
voiding
IPSS  
storage
IPSS  
QoL
Qmax  
(mL/sec)
PVR  
(mL)
Total 533 70.8±8.1 51.0±32.7 4.5±27.9 21.0±8.0 12.3±5.3 8.5±3.8 4.1±1.2 9.1±22.2 119.8±194.2
Prostate size
Under 80 458 70.5±8.1a) 43.5±14.8a) 3.6±20.7a) 20.9±7.9 12.3±5.3 8.5±3.8 4.1±1.1 9.6±23.8a) 115.4±199.2a)
Over 80 75 73.2±8.0 111.1±62.5 25.1±59.9 21.1±7.8 12.6±5.4 8.5±3.5 3.8±1.6 5.5±5.8 154.6±163.6
Anticoagulant
None 411 70.3±8.3a) 50.2±34.2 4.9±30.7 21.1±7.8 12.5±5.1 8.5±3.8 4.2±1.1 9.1±22.0 113.2±164.8
Yes 122 72.4±7.5 53.3±27.3 3.9±14.9 20.4±8.6 11.7±5.9 8.5±3.6 3.9±1.4 9.1±22.8 139.5±263.3
5-ARI medication
None 512 70.7±8.1 51.0±33.0 9.7±28.4a) 21.0±8.1 12.3±5.3 8.5±3.8 4.1±1.2 9.2±22.7 120.1±196.1
Yes 21 73.1±7.9 50.4±25.3 3.5±4.1 20.8±6.3 12.4±5.2 8.1±3.4 3.5±1.2 7.6±5.6 115.0±154.7
AUR Hx
None 432 70.3±7.8a) 48.4±23.4a) 3.8±26.2a) 20.9±8.0 12.2±5.2 8.5±3.8 4.1±1.1 9.9±24.3 106.3±184.9a)
Yes 101 72.2±9.3 62.4±57.0 16.5±33.4 21.5±8.2 12.9±5.9 8.5±3.8 4.2±1.4 5.5±5.5 180.0±222.5
TURP Hx
None 488 70.6±8.2a) 51.6±33.5 3.4±27.5 20.8±8.1 12.3±5.3 8.4±3.8 4.1±1.1 8.6±19.8 123.9±200.1a)
Yes 47 73.2±7.0 43.7±20.6 4.1±32.4 22.3±7.5 12.9±5.5 9.2±3.6 4.3±1.15 15.5±41.7 68.4±76.5
Values are presented as mean±standard deviation.
TRUS, transrectal ultrasonography of prostate; PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score; QoL, quality of life; Qmax, 
maximum urinary flow; PVR, post-voided residual urine; 5-ARI, 5-alpha reductase inhibitor; AUR, acute urinary retention; Hx, history ; TURP, transure-
thral resection of the prostate.
a)P<0.05 compared with intragroup comparison.
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Fig. 1.  Changes in International Prostate Symptom Score (IPSS) 
after 120-W GreenLight High-Performance System laser photo 
vaporization of the prostate in the total group of patients. QoL, 
quality of life. *P<0.05 compared with preoperative (Preop) value.
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Fig. 2. Changes in International Prostate Symptom Score (IPSS) after 120-W GreenLight High-Performance System laser photo vapor-
ization of the prostate in each group. QoL, quality of life; 5-ARI, 5-alpha reductase inhibitor; AUR, acute urinary retention; Hx, history; 
TURP, transurethral resection of the prostate. *P<0.05 compared with preoperative (Preop) value.
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about 8% of the patients during the first postoperative month, 
the symptom disappeared after starting medication or ob-
servation in most cases. Retrograde ejaculation occurred in 
about 13% of patients. 
DISCUSSION
BPH is one of the fastest-growing diseases in the elderly 
population [1]. The QoL in the elderly population has been 
underscored as the number of elderly people has increased 
along with prolonged life expectancy [4]. Voiding difficulty is a 
leading symptom that has a devastating effect on QoL in older 
people. Moreover, LUTS generated by BPH may result in mood 
disorders such as depression and can impair social relation-
ships [2]. To relieve such BPH symptoms, medications are 
prescribed including alpha-blockers and 5-ARIs. However, 
medical treatment focuses on improving symptoms instead 
of resolving the main causes of BPH. Medical treatment may 
require long-term intake of medication, may result in the recur-
rence of symptoms upon the suspension of medication, and 
may take a long time to alleviate symptoms. 
 For the treatment of mechanical obstruction due to the 
enlarged prostate, surgical treatment is the fundamental 
method. Hence, TURP has been recommended as one of the 
standard choices [5]. However, TURP has the potential risk 
of operative site bleeding or delayed bleeding and requires a 
long postoperative hospitalization period. In addition, the oc-
currence of postoperative complications such as retrograde 
ejaculation has been pointed out [6-8]. To resolve such short-
comings, different surgical procedures and instruments have 
been devised. Among these, laser resection of the prostate has 
drawn attention recently. Laser resection of the prostate using 
the neodymium-doped:YAG (Nd:YAG) laser converts most of 
the energy into heat. However, this procedure performed in 
the early stages may require long bladder drainage and hospi-
talization periods; its shortcomings also include a higher risk 
of reoperation [9]. The 80-W potassium-titanyl-phosphate 
(KTP) laser introduced afterwards has a shorter wavelength 
than the Nd:YAG laser. Moreover, the laser is more favorable 
for removing prostate adenoma without bleeding during the 
TURP procedure owing to its photo-selectivity and high reac-
tivity to heme protein [10]. However, the 80-W KTP laser has 
the shortcoming of a long operating time owing to insufficient 
output-generating capacity. The 120-W GreenLight laser used 
by the authors has a more powerful output generating capac-
ity compared with the 80-W laser, which enables the removal 
of large amounts of tissue in a shorter time. Moreover, its post-
operative efficacy has been verified by numerous studies [4].
Table 2. The results of repeated-measures analysis of variance comparing the difference in preoperative and postoperative parame-
ters in each group
Variable IPSS total IPSS voiding IPSS storage IPSS QoL Qmax PVR
Prostate size 80
P-value 0.014a) 0.001a) 0.001a) 0.001a) 0.002a) 0.024a)
Intergroup comparison 0.851 0.506 0.230 0.045a) 0.770 0.991
Adjusted P-value 0.487 0.553 0.391 0.747 0.506 0.854
Anticoagulant medication
P-value 0.001a) 0.03a) 0.015a) 0.001a) 0.001a) 0.001a)
Intergroup comparison 0.271 0.866 0.988 0.755 0.698 0.240
Adjusted P-value 0.862 0.431 0.665 0.691 0.936 0.067
5-ARI medication Hx
P-value 0.003a) 0.006a) 0.001a) 0.021a) 0.009a) 0.03a)
Intergroup comparison 0.161 0.105 0.404 0.617 0.745 0.614
Adjusted P-value 0.696 0.762 0.104 0.103 0.687 0.758
AUR Hx
P-value 0.001a) 0.001a) 0.001a) 0.001a) 0.001a) 0.001a)
Intergroup comparison 0.003a) 0.087 0.129 0.099 0.152 0.344
Adjusted P-value 0.576 0.621 0.847 0.389 0.336 0.570
TURP Hx
P-value 0.007a) 0.037a) 0.034a) 0.001a) 0.001a) 0.620
Intergroup comparison 0.929 0.858 0.866 0.547 0.138 0.296
Adjusted P-value 0.098 0.429 0.547 0.299 0.311 0.929
IPSS, International Prostate Symptom Score; QoL, quality of life; Qmax, maximum urinary flow; PVR, post-voided residual urine; 5-ARI, 5-alpha reduc-
tase inhibitor; Hx, history; AUR, acute urinary retention; TURP, transurethral resection of the prostate.
a)P<0.05 compared with preoperative value.
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 Along with the advancement of laser resection of the pros-
tate, surgical cases that were considered inoperable or ex-
tremely high-risk in the past have been attempted. One such 
case is the use of laser resection of the prostate in patients 
administered oral anticoagulants [11]. Patients take oral an-
ticoagulants for various reasons. However, one of the most 
common and critical reasons is prevention of complications 
when a patient has cardiovascular and related diseases as the 
underlying disease [12]. The bleeding risk increases when 
surgery is performed on a patient currently taking oral antico-
agulants. To conduct the TURP procedure, the administration 
of oral anticoagulants is generally suspended before surgery. 
Consequently, this has imposed burdens on surgeons with 
the higher risk of potential deep vein thrombosis and car-
diovascular and related problems [13]. However, the 120-W 
GreenLight HPS laser PVP minimizes the potential risks dur-
ing the operation owing to the laser’s unique characteristic 
of photo-selectivity. These findings were verified through the 
process of examining cases requiring postoperative transfu-
sion or reoperation because of bleeding. Significant improve-
ment was observed in terms of postoperative storage and 
voiding symptoms, Qmax, and PVR from preoperative values. 
The outcomes were verified to align with the results of previ-
ous studies. Therefore, the 120-W laser is thought to be safe 
and effective for patients taking oral anticoagulants as proven 
by this study and others.
 Longer operating hours are required as the size of the pros-
tate gets larger, which may eventually lead to increased mor-
bidity as a result of the delayed operating time. In the HPS 
laser PVP procedure, the operating time may be longer than 
that for conventional TURP and the efficacy may be reduced. 
These limitations of the HPS laser PVP procedure have been 
pointed out in the case of larger prostate volumes [14,15]. 
However, no differences were found in patients’ subjective 
improvement in symptoms and improvement in objective 
urinary indicators excluding QoL, as seen in recent data and 
the present study results after the HPS laser PVP procedure 
[16]. However, the possibilities of an effect of prostate volume 
on QoL have to be taken into consideration, because the clas-
sification of patients according to prostate volume includes 
BPH and additionally diagnosed prostate cancer.  The possible 
influence on the QoL cannot be excluded.
 5-ARIs are commonly prescribed to reduce the prostate 
volume of patients diagnosed with an enlarged prostate in 
urology clinics, primary hospitals, and nonurology clinics 
or to improve preoperative LUTS. This medication is known 
to be effective in reducing an enlarged prostate volume and 
the likelihood of increased Qmax and the occurrence of AUR 
[17-19]. Regarding the effect of 5-ARIs on surgery utilizing 
conventional TURP, a study reported that there were no nega-
tive effects on preoperatively reduced prostate volume, risk of 
operative site bleeding, or postoperative observation during 
the follow-up period [20]. In addition, a similar study result 
was acquired during prostate resection with the 80-W KTP 
laser [21,22]. Significant improvement in symptoms was con-
firmed in the comparison of preoperative and postoperative 
values with the use of 120-W HPS laser PVP. The postopera-
tive improvement in symptoms was not affected by the intake 
of a 5-ARI before the operation. Thus, preoperative intake of a 
5-ARI is thought to have no negative effects during the 120-W 
HPS laser PVP procedure as shown in the present study. 
 AUR is not only a symptom of BOO caused by BPH but 
can also be associated with detrusor underactivity. Although 
these two symptoms are usually distinctively differentiated, 
they are commonly associated. Hence, this may lead to LUTS 
or AUR, and treating BOO with the use of a laser is reported 
to be critical in symptom relief and improving functional 
impairment [23]. If AUR is left untreated, permanent damage 
to the detrusor muscle and upper urinary tract deterioration 
can occur. Thus, AUR needs to be swiftly treated. The present 
study confirmed improvement in all parameters upon the 
elimination of BOO through surgery with 120-W HPS laser 
PVP. A preoperative history of AUR did not seem to have a 
great influence on postoperative progress. If BOO is elimi-
nated, most AUR induced by BPH can be resolved. Favorable 
results are anticipated regardless of the preoperative history 
of AUR if BOO is sufficiently treated.
 In cases of a preoperative history of TURP, the pressure of 
a second operation is felt by both surgeons and patients in 
most cases. The burden is heavier when LUTS recur owing to 
BPH after TURP. In the present study, desirable results were 
acquired when laser resection of the prostate was conducted. 
The efficacy was sustained for a follow-up period of more than 
1 year. Moreover, no significant differences were observed in 
either group categorized on the basis of a previous history of 
prostate resection. Thus, the results of the present study sug-
gest that laser ablation of the prostate does not have negative 
effects in a second operation. A similar or lower retrograde 
ejaculation rate was verified in laser surgery compared with 
TURP [24]. 
 This outcome suggests that laser surgery may be more de-
sirable for preventing postoperative retrograde ejaculation 
after TURP. 
 The present study aimed to report the results of laser re-
section of the prostate performed on more than 500 patients 
for the last 3 years. The study distinctively investigated the 
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preoperative and postoperative effects of laser resection of 
the prostate on subjects including different unique cases. The 
safety and efficacy of laser resection of the prostate has been 
reconfirmed, because no cases of death, transfusion, or reop-
eration occurred. 
 There were some limitations to this study. The nature of the 
study was retrospective but not randomized. Moreover, there 
is the likelihood of bias because the research and operations 
were conducted in a tertiary hospital. To overcome such fail-
ings, larger prospective and randomized studies are thought 
to be essential. Although this study was conducted for about 3 
years, the maximum follow-up period was confined to 1 year. 
To verify the efficacy, a longer postoperative observational 
period is thought to be crucial. 
 In conclusion, laser resection of the prostate is safe and ef-
fective. The results of the HPS laser PVP procedure were not 
influenced by the size of prostate, the use of anticoagulants, 
the intake of 5-ARI for BPH management, a history of AUR, 
a history of TURP, or other factors. Thus, this study was able 
to reconfirm the efficacy and safety of laser resection of the 
prostate.
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